COMPASS Pathways: Pay

COMPASS Pathways paid its 3 named executives $4.1M in total in FY2025 (Dec). CEO Kabir Nath was paid $2.1M of that.

Pay$100 in the stock at the end of FY21 → $31
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Kabir NathChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Teri LoxamChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Guy GoodwinChief Medical Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years

CEO pay against the pay peers

In FY2024 (Dec), the median CEO pay of the 6 peers with pay on file was $7.6M. CEO pay of COMPASS Pathways for that year is not on file.

  1. 1Kymera Therapeutics
  2. 2CareDx
  3. 3Scholar Rock Holding
  4. 4Arcus Biosciences
  5. 5Rocket Pharmaceuticals
  6. 6Bicycle Therapeutics
  7. 7COMPASS PathwaysNot disclosed
  8. 8AC Immune SANot disclosed
  9. 9ATAI Life Sciences SANot disclosed
  10. 10Adaptimmune Therapeutics plcNot disclosed
  11. 11Alector, Inc.Not disclosed
  12. 12Autolus TherapeuticsNot disclosed
  13. 13BioXcel Therapeutics, Inc.Not disclosed
  14. 14Centessa Pharmaceuticals plcNot disclosed
  15. 15Crinetics Pharmaceuticals, Inc.Not disclosed
  16. 16Exscientia plcNot disclosed
  17. 17Merus N.V.Not disclosed
  18. 18Mind Medicine (MindMed) Inc.Not disclosed
  19. 19Praxis Precision Medicine, Inc.Not disclosed
  20. 20Prothena Corporation plcNot disclosed
  21. 21PureTech Health plcNot disclosed
  22. 22Replimmune Group, Inc.Not disclosed
  23. 23Y-mAbs Therapeutics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.